Oriens Travel & Hotel Management Corp. (OTHM) on Track with Acquisition Strategy
August 5, 2014 (www.investorideas.com newswire) Oriens Travel & Hotel Management Corp. announced today that it has formally started the process involved in financing the Jaco Beach acquisition while its Costa Rican partners have begun drawing down capital from traditional, non-toxic, asset based capital resources. It was reported that management will pursue financing in a two-part strategy – seeking traditional asset back financings to bridge capital and to secure larger long-term equity based financing.
"Acquiring properties comes with a number of expenses; costs we have diligently looked to cover with the least amount of impact on the market," stated Ken Chua, President of Oriens Travel & Hotel Management. "While we understand the second phase of our multi-million dollar raise will eventually incorporate long-term equity financing, current expenses are just below half a million dollars. We find it very important to responsibly facilitate this smaller size funding, though a financing vehicle offering the greatest benefit to our market and stakeholders. Through our allied partners in Costa Rica, along with friendly investors in the States, we have seemingly been fortunate enough — so far, to access capital without registering or selling any corporate stock."
As a result of Costa Rica's recent World Cup success, closing is expected to be delayed by approximately three weeks. It is worth noting, however, that due to the strength of Oriens' alliances, additional flexibility was granted and thus gave Oriens the ability to satisfy obligations inherent to a variety of its deal structures.
Mr. Chua added, "This process has certainly been challenging. What keeps us focused however, is the sheer value and confidence we expect will ultimately be delivered to our shareholders. When Oriens completes these acquisitions, re-launches our FROL, and begins managing new properties under a retooled brand, we are absolutely confident that our diligence will prove worthwhile. The time, dedication and commitment made by Oriens, our allied partners and those local investors who have extended us the opportunity to exhibit our competencies, will not be in vain."
OTHM engages in the operation of hotels and resorts primarily in the United States and Central America under the Hotel PURE brand. The company also operates Friendly Reservations Online, a proprietary and sophisticated online booking system designed to execute reservations captured through Hotel PURE consumer facing websites, as well as individual hotel websites operated by Oriens on behalf of hotels branded under the Hotel PURE brand.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Stellar Biotechnologies, Inc. (SBOTF) Collaborates to Develop Therapeutic Vaccines
Stellar Biotechnologies is powering and improving the swiftly-evolving field of immunotherapy. The California-based company is a leader in the sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), and committed to applying its KLH platform to the creation and enhancement of drug therapies that activate the body's immune system in order to treat disease.
KLH is a multipurpose molecule that can be joined with a disease-targeting agent to create a new immunotherapy, or used alone to measure the body's immune response to drugs. It is a high molecular weight (HMW) and an important immune-stimulating protein with a history of safe, effective use in therapeutic vaccine development. KLH is used in immunotherapy and diagnostic markets to target cancers, infectious diseases, and immune disorders (including Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, lymphoma, metastatic breast cancer and prostate cancer).
Stellar Biotech has made a breakthrough in the science and supply of KLH. To support its commitment to excellence in targeted immune therapies and immunodiagnostics, it has developed the proprietary ability to sustainably produce the vital KLH molecule, and set new benchmarks for its manufacture as well as the protection of its natural marine source. KLH can only be obtained from a rare marine source, the Giant Keyhole Limpet, but the company's landmark achievements in aquaculture science ensure the production of quality KLH while protecting its source.
Stellar Biotech's proprietary methods, facilities, and KLH technology make it unique and allow it to meet the rising demand for the commercial-scale supply of good manufacturing practice (GMP) grade KLH to ensure environmentally-sound KLH production as well as develop KLH-based active immunotherapies. The company's current product offerings include: KLH pharmaceutical intermediates; HMW and subunit KLH protein in various grades, formulations, and configurations; and preclinical in vitro diagnostic kits.
Stellar Biotech has a number of active collaborations in the works:
In June 2014, Neovacs, a French biotech company and long-time customer of Stellar Biotechnologies, shared an update on its immunotherapy programs and pipeline for autoimmune disease. During an interview with Neovacs' CEO Miguel Sieler, Mr. Sieler discussed the company's use of Stellar KLH as the carrier molecule in three of its products now in clinical development. Neovacs develops vaccines that stimulate a patient's immune system and allow it to produce monoclonal antibodies to target a pre-specified autoimmune disease; in this case, the products are set to target Rheumatoid Arthritis, Crohn's Disease, and Lupus.
Stellar is also working with OBI Pharma, a Taiwanese biopharmaceuticals manufacturer, to develop and evaluate manufacturing methods for an active immunotherapy that targets metastatic breast cancer and uses Stellar's GMP-grade KLH. The concept behind the therapy, designated OBI-822, is to use the human body's immune system to fight cancer with few side effects, unlike chemotherapy and radiation therapy that harm good cells along with cancerous cells. In late July 2014, OBI Pharma announced that its phase 2/3 stage clinical trial for OBI-822 has met the goal of collecting 342 patients. The clinical test project was designed as a multinational, randomized control trial, with 45 medical centers in Taiwan, Hong Kong, South Korea, India and the United States participating. The company's chairman Michael N. Chang commented that the OBI-822 project is progressing smoothly and the completion of the patient collection was a major milestone. The next step is to analyze the data from the clinical test after the last patient completes the treatment process.
For more information on the company or other collaborations, visit www.stellarbiotech.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.